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Background: Insulin resistance, the primary mechanism of metabolic syndrome,
promotes gastric carcinogenesis. Metabolic syndrome is associated with sarcopenia.
We aimed to investigate the association between sarcopenia and gastric carcinogenesis,
including precancerous conditions such as atrophic gastritis (AG), intestinal metaplasia
(IM), and dysplasia.
Methods: The study included adult patients who underwent gastroduodenoscopy at a
checkup center. AG and IM were evaluated using endoscopy. Based on muscle mass,
sarcopenia was defined as a skeletal muscle index <1 standard deviation below the
sex-specific mean for healthy adults aged 20–39 years (cutoff point: 29.3% for males
and 26.7% for females). Obesity was defined as a body mass index (BMI) ≥25 kg/m2
according to the Asia-Pacific criteria. Sarcopenic obesity was defined as a combination of
sarcopenia and obesity. The association between gastric carcinogenesis and sarcopenia
was evaluated.
Results: Among 8,356 enrolled participants, 0.14 and 42.5% were diagnosed with
gastric cancer and precancerous conditions, respectively. Approximately 41.7% of
gastric cancer patients and 16.9% of patients with precancerous conditions were
diagnosed with sarcopenia. Both sarcopenic obesity (odds ratio [OR] = 4.139, P =
0.016) and diabetes mellitus (DM) (OR = 5.152, P = 0.005) were significantly associated
with gastric cancer. Sarcopenia, DM, hypertension, dyslipidemia, Helicobacter pylori
infection, smoking, and alcohol consumption were significantly associated with
precancerous conditions.
Conclusions: Sarcopenia and sarcopenic obesity were associated with gastric
carcinogenesis and may be novel risk factors for gastric carcinogenesis.
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INTRODUCTION
Gastric cancer is one of the commonest malignancies, especially
in East Asian countries, such as Korea and Japan (1). Although
people aged ≥40 years in Korea undergo biannual endoscopy
as part of the National Cancer Screening program, Korea
remains one of the countries with the highest incidence of
gastric cancer in the world (2). For this reason, it is important
to not only detect precancerous conditions or early gastric
cancer through screening endoscopy but also control modifiable
risk factors. Gastric cancer is a multistep and multifactorial
disease. Precancerous conditions, including atrophic gastritis
(AG), intestinal metaplasia (IM), and dysplasia, progress to
gastric cancer because of multiple influencing factors (3, 4).
To date, several risk factors such as Helicobacter pylori
infection, diabetes mellitus (DM), obesity, smoking, alcohol
consumption, and diet, including the consumption of salty
or smoked foods, are known to be associated with gastric
carcinogenesis (5, 6). Among these factors, DM and obesity
are components of metabolic syndrome. Insulin resistance,
the primary mechanism of metabolic syndrome, promotes
the carcinogenesis of various malignancies, including gastric
cancer (7).
Sarcopenia is defined as the progressive loss of muscle mass
and function as a result of the aging process. It has been
recognized as a major health problem because of its association
with the risk of adverse outcomes, such as physical disability,
poor quality of life, and death (8). With the aging of population,
the prevalence of sarcopenia has been increasing, although it
can vary according to the definition, method used to measure
muscle mass, age, race, and sex (9, 10). When the BIA method
was used, the prevalence in the non-Asian population was
higher than that in the Asian population for men (19 vs.
10%), and the prevalence in the non-Asian population was
higher than that in the Asian population for women (20 vs.
11%). When dual-energy X-ray absorptiometry (DXA) was used,
the prevalence in the Asian population was higher than that
in the non-Asian population for men (9 vs. 6%), and the
prevalence in the non-Asian was higher than that in the Asian
population for women (10 vs. 6%). Previous studies reported that
sarcopenia is associated with metabolic syndrome. As skeletal
muscle is the primary tissue responsible for insulin-dependent
glucose uptake, sarcopenia is associated with systemic insulin
resistance, which progressively induces metabolic syndrome (11,
12). Recently, a “new concept,” sarcopenic obesity, which refers
to the coexistence of sarcopenia and obesity and which are
both associated with metabolic syndrome, has a greater effect on
metabolic disease, morbidity, and mortality than sarcopenia and
obesity individually (13).
Because both gastric carcinogenesis and sarcopenia are
associated with metabolic syndrome, we hypothesized that there
is an association between gastric carcinogenesis and sarcopenia.
To the best of our knowledge, only a limited number of studies
have demonstrated this relationship. Hence, this study aimed
to investigate risk factors for gastric carcinogenesis with a
focus on sarcopenia and sarcopenic obesity among patients who
underwent routine health checkups.
MATERIALS AND METHODS
Study Design and Population
This single-center study was conducted at Gangnam Severance
Hospital, Seoul, Korea fromAugust 2017 to August 2018. Starting
in August 2017, our checkup center could measure skeletal
muscle index (SMI). Data were retrospectively collected from
electronic medical records of patients who visited our center
for a routine health checkup. Overall, 9,332 Korean patients
who underwent upper endoscopy at our checkup center were
considered for this study. We excluded 976 patients with a
history of gastric cancer or any type of cancer (n = 869); a
history of gastric surgery, including resection of the stomach or
gastrectomy (n= 65); and incomplete electronic medical records
(n = 42). As a result, 8,356 patients were eligible and were
enrolled in this study.
The study protocol conformed to the ethical guidelines of
the World Medical Association Declaration of Helsinki and
was approved by the Gangnam Severance Hospital Institutional
Review Board (IRB No. 3-2018-0349). Informed consent was
not required because this study was a retrospective analysis of
existing administrative and clinical data.
Anthropometric Measurements
Anthropometric parameters of all enrolled patients were
measured. Body weight and height were measured to the nearest
0.1 kg and 0.1 cm, respectively, with the patients wearing light-
weight clothing without shoes. To measure skeletal muscle
mass, we used multi-frequency bioelectrical impedance analysis
(ACCUNIQ BC 720; SELVAS healthcare, Korea), which is
considered an appropriate alternative to DXA (14). Appendicular
skeletal muscle mass (ASM) was calculated as the sum
of appendicular lean mass from both the arms and legs
(15). BMI was calculated as body weight divided by height
squared (kg/m2).
We used the definition of sarcopenia developed by Janssen
et al. (16); they adopted SMI to establish the prevalence of
sarcopenia and defined sarcopenia as an SMI <1 standard
deviation below the sex-specific mean for healthy adults aged
20–39 years. SMI was calculated as ASM/body weight ×
100 (%). In our study, the cutoff value for sarcopenia was
29.3% for males and 26.7% for females. We defined obesity
as BMI ≥25 kg/m2 according to the Asia-Pacific criteria (17).
Sarcopenic obesity was defined as the coexistence of sarcopenia
and obesity.
Questionnaire
All patients who visited our checkup center were required to
complete a questionnaire. The questionnaire included questions
on combined DM, hypertension, dyslipidemia, smoking history,
alcohol consumption, and diet (consumption of salty and
spicy foods). Regarding diet, patients were asked to select
“yes” if they consumed salty and spicy foods six times
within 7 days.
Endoscopic Evaluation of the Stomach
All enrolled patients underwent endoscopic examinations
using an endoscope (GIF-H260; Olympus Medical Systems,
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Tokyo, Japan) equipped with an electronic endoscopy system
(EVIS LUCERA; Olympus Medical Systems). H. pylori infection
was detected using the following methods: rapid urease
test (CLO test; Delta West, Bentley, Australia), pathology
(Giemsa staining), and immunoglobulin G specific for
H. pylori in the serum (enzyme-linked fluorescence assay,
Vidas [bioMerieux Vitek, Inc. Hazelwood, MO, USA]). If
the result of at least one of these three tests was positive,
the patient was diagnosed with H. pylori infection. Gastric
cancer and gastric dysplasia were confirmed by histologic
examination of the tissue obtained during endoscopic biopsy.
AG and IM were diagnosed based on the gross endoscopic
findings reported by endoscopists with at least 3 years
of experience.
Statistical Analysis
Continuous variables were reported as mean ± standard
deviation and were compared between groups using the t-test
or Wilcoxon rank-sum test. Categorical variables were reported
as numbers and percentages, and the chi-square test or Fisher’s
exact test was used to compare categorical variables.
Pearson’s correlation analysis was used to evaluate the
correlation between two continuous variables. We performed
multivariate Cox regression analysis to identify the risk
factors affecting gastric cancer and precancerous conditions.
We performed two multivariate analyses because sarcopenic
obesity is a combination of sarcopenia and obesity. Statistical
analysis was performed using SPSS version 23.0 (IBM Corp.,




Table 1 shows the baseline characteristics of the study
population. Of 8,356 patients, 4,670 (55.9%) were men, and
the mean age was 49.1 ± 11.6 years. The average BMI was
23.9 ± 3.3 kg/m2. The mean SMI was 32.2 ± 2.7% in men
and 28.7 ± 3.0% in women. Approximately 15.2% of patients
were diagnosed with sarcopenia and 13.5% were diagnosed with
sarcopenic obesity. Male subjects had a higher prevalence of
sarcopenia (18.8% male vs. 10.6% female) and sarcopenic obesity
(17.3% men vs. 8.7% women). Approximately 11.2% of patients
had DM, 14.3% had dyslipidemia, and 18.7% had hypertension.
Overall, 12 patients had gastric cancer. Moreover, 3,622 patients
were diagnosed with gastric precancerous conditions. Among
these patients, 2,205 had AG, 1,407 had IM, and 10 had
gastric dysplasia.
Risk Factors for Gastric Cancer
Tables 2, 3 show the risk factors for gastric cancer. In the
univariate analysis, advanced age, obesity, sarcopenia, sarcopenic
obesity, and DM were significantly associated with an increased
risk of gastric cancer (Table 2). In the multivariate analyses,
sarcopenic obesity (odds ratio [OR] = 4.139, 95% confidence
interval [CI]: 1.304–13.133, P = 0.016) and DM (OR = 5.152,
TABLE 1 | Baseline characteristics of the study population.
Characteristics All patients (N = 8,356)
Age (years, mean ± SD) 49.1 ± 11.6
Male (n, %) 4,670 (55.9)
Height (cm, mean ± SD) 166.5 ± 8.5
Weight (kg, mean ± SD) 66.5 ± 12.8
BMI (kg/m2, mean ± SD) 23.9 ± 3.3
Obesity (n, %) 2,839 (34.0)
SMI (%, mean ± SD)
Male 32.2 ± 2.7
Female 28.7 ± 3.0
Current smoker (n, %) 1,479 (17.1)
Alcohol history (n, %) 5,593 (66.9)
DM (n, %) 940 (11.2)
Dyslipidemia (n, %) 1,192 (14.3)
Hypertension (n, %) 1,563 (18.7)
Sarcopenia (n, %) 1,270 (15.2)
Male 878/4,670 (18.8)
Female 392/3,686 (10.6)
Sarcopenic obesity (n, %) 1,129 (13.5)
Male 810/4,670 (17.3)
Female 319/3,686 (8.7)
Diet, salty and/or spicy (n, %) 3,398 (40.7)
H. pylori infection (n, %) 1,217 (14.6)
Gastric cancer (n, %) 12 (0.14)
Gastric precancerous conditions (n, %) 3,622 (43.3)
Atrophic gastritis (n, %) 2,205 (26.4)
Intestinal metaplasia (n, %) 1,407 (16.8)
Dysplasia (n, %) 10 (0.12)
BMI, body mass index; SMI, skeletal muscle index; DM, diabetes mellitus; H. pylori,
Helicobacter pylori.
95% CI: 1.624–16.347, P= 0.005) were significant risk factors for
gastric cancer (Table 3).
Risk Factors for Gastric Precancerous
Conditions
Tables 4, 5 show the risk factors for gastric precancerous
conditions. In the univariate analysis, advanced age, obesity,
smoking, alcohol consumption, sarcopenia, sarcopenic obesity,
H. pylori infection, DM, dyslipidemia, hypertension, and diet,
which included consumption of salty and/or spicy foods, were
significantly associated with gastric precancerous conditions
(Table 4). Among these factors, sarcopenia (OR = 1.201, 95%
CI: 1.039–1.387, P = 0.013) was independently associated with
gastric precancerous conditions. Moreover, smoking (OR =
1.195, 95% CI: 1.081–1.320, P = 0.001), alcohol consumption
(OR= 1.316, 95% CI: 1.189–1.456, P < 0.001), DM (OR= 1.533,
95% CI: 1.320–1.782, P < 0.001), hypertension (OR= 1.412, 95%
CI: 1.244–1.603, P < 0.001), dyslipidemia (OR = 1.552, 95% CI:
1.357–1.775, P < 0.001), and H. pylori infection (OR = 3.954,
95% CI: 3.454–4.057, P < 0.001) were independent risk factors
for gastric precancerous conditions (Table 5).
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Age (years, mean ± SD) 49.0 ± 11.6 58.8± 13.8 0.003
Male (n, %) 4,633 (55.9) 7 (58.3) 0.864
Obesity (n, %) 2,831 (33.9) 8 (66.7) 0.028
Current smoker (n, %) 1,477 (17.7) 2 (16.7) 1.000
Alcohol history (n, %) 5,588 (67.0) 5 (41.7) <0.001
DM (n, %) 935 (11.2) 5 (41.7) 0.007
Dyslipidemia (n, %) 1,190 (14.3) 2 (16.7) 0.685
Hypertension (n, %) 1,158 (18.7) 5 (41.7) 0.056
Diet, salty and/or spicy (n, %) 3,391 (40.6) 7 (58.3) 0.247
H. pylori infection (n, %) 1,213 (14.5) 4 (33.3) 0.084
Sarcopenia (n, %) 1,265 (15.2) 5 (41.7) 0.025
Sarcopenic obesity (n, %) 1,124 (13.5) 5 (41.7) 0.016
DM, diabetes mellitus; H. pylori, Helicobacter pylori.
TABLE 3 | Multivariate analyses of the risk factors for gastric cancer.
Multivariate analysis 1 Multivariate analysis 2

















OR, odds ratio; DM, diabetes mellitus; CI, confidence interval.
Multivariate analysis 1: Adjusted for DM, sarcopenia, and obesity. Multivariate analysis 2:
Adjusted for DM and sarcopenic obesity.
DISCUSSION
Our study showed that sarcopenia and sarcopenic obesity
were significantly associated with gastric carcinogenesis.
A possible explanation for these associations might be
related to metabolic syndrome. DM, hypertension, and
dyslipidemia, which are components of metabolic syndrome,
are also significantly associated with gastric carcinogenesis in
our study.
As reported in previous studies, DM is considered a
risk factor for gastric cancer (18–21). There are several
suggested mechanisms to explain the pathogenic role of
DM in gastric carcinogenesis. Patients with hyperglycemia
may develop insulin resistance, and an increase in insulin
levels may induce cell proliferation. This process may cause
changes in the gastric mucosa and genetic alterations,
eventually leading to gastric carcinogenesis (22). Increases
in reactive oxygen species caused by DM and high glucose
levels are associated with mutational changes in oncogenes









Age (years, mean ± SD) 46.0 ± 11.0 53.2 ± 11.0 <0.001
Male (n, %) 2,663 (55.2) 2,000 (56.8) 0.156
Obesity (n, %) 1,591 (33.0) 1,240 (35.2) 0.035
Current smoker (n, %) 1,848 (38.3) 1,475 (41.9) 0.001
Alcohol history (n, %) 1,487 (30.8) 1,269 (36.0) <0.001
DM (n, %) 407 (8.4) 528 (15.0) <0.001
Dyslipidemia (n, %) 556 (11.5) 634 (18.0) <0.001
Hypertension (n, %) 737 (15.3) 821 (23.3) <0.001
Diet, salty and/or spicy (n, %) 1,903 (39.5) 1,488 (42.2) 0.011
H. pylori infection (n, %) 375 (7.8) 838 (23.8) <0.001
Sarcopenia (n, %) 671 (13.9) 594 (16.9) <0.001
Sarcopenic obesity (n, %) 610 (12.7) 514 (14.6) 0.010
DM, diabetes mellitus; H. pylori, Helicobacter pylori.
TABLE 5 | Multivariate analyses of the risk factors for gastric
precancerous conditions.
Multivariate analysis 1 Multivariate analysis 2





















































OR, odds ratio; DM, diabetes mellitus; H. pylori, Helicobacter pylori; CI,
confidence interval.
Multivariate analysis 1: Adjusted for smoking, alcohol, DM, hypertension, dyslipidemia, H.
pylori infection, diet, sarcopenia, and obesity. Multivariate analysis 2: Adjusted for smoking,
alcohol, DM, hypertension, dyslipidemia, H. pylori infection, diet, and sarcopenic obesity.
and tumor suppressor genes. This change contributes to
gastric carcinogenesis (23, 24). The increase in insulin-
like growth factors in DM patients plays an important
role in the initiation, progression, and metastasis of gastric
cancer (25).
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In our study, H. pylori infection is significantly associated
with precancerous conditions. H. pylori infection is a well-
known risk factor for gastric carcinogenesis as reported in
previous studies. Moreover, one prospective study reported
that DM and H. pylori infection have synergistic effects on
gastric carcinogenesis (26). DM may increase the risk of gastric
carcinogenesis by stimulating epithelial cell proliferation, which
is the initial step in the cascade of gastric carcinogenesis, because
of the presence of H. pylori. H. pylori infection stimulates
pancreatic insulin release by increasing gastrin secretion and
decreasing the serum somatostatin level (27, 28). One clinical
study reported that patients with H. pylori infection have higher
insulin resistance (29).
Meanwhile, the association between hypertension and gastric
cancer is unclear. However, a previous study explained that
gastric cancer and hypertension have a common biochemical
pathway. Increased levels of inositol triphosphate and cytosolic
calcium are involved in the pathogenesis of hypertension and
carcinogenesis stage (30).
Previous studies reported the association between obesity
and gastric carcinogenesis. A clinical study showed that the
effect of obesity on gastric cancer may differ depending on sex
(31). In males, obesity was associated with an increased risk
of early gastric cancer and well or moderately differentiated
adenocarcinoma. In females, obesity was associated with gastric
dysplasia regardless of H. pylori infection. One meta-analysis
conducted in a cohort and case-control study reported that
obesity was associated with the risk of gastric cancer in male and
non-Asian patients (32). This study showed that both overweight
and obesity were associated with the risk of gastric cardia cancer.
In our study, obesity was not significantly associated with an
increased risk of gastric carcinogenesis. This finding may be due
to the fact that stratified analysis was not performed according
to sex and the location of the cancer. However, sarcopenic
obesity, combined with sarcopenia and obesity, is a risk factor
for gastric cancer. Recent studies have shown that sarcopenic
obesity affects the development of cardiometabolic diseases (33–
37). These studies also reported that sarcopenic obesity has a
strong relationship with metabolic syndrome and is associated
with a higher risk of metabolic disorders and mortality than
obesity or sarcopenia alone.
In 1998, Baumgartner et al. first defined sarcopenia as
ASM/height2 (kg/m2) <2 standard deviations below the mean
of a young reference group (38). Although several different
definitions of sarcopenia have since been suggested (38, 39),
a widely accepted definition suitable for use in research
and clinical practice is still pending because of a lack of
consensus (8, 13). Similar to gastric carcinogenesis, age-
related sarcopenia is also associated with the development of
metabolic syndrome. The expression of glucose transporter
type 4, which facilitates the uptake of glucose, is related
to the volume of skeletal muscle fiber (40). Therefore,
sarcopenia can cause insulin intolerance that leads to metabolic
syndrome. Sarcopenia andmetabolic syndrome develop a vicious
cycle (41). The loss of muscle mass because of sarcopenia
results in decreased physical activity, causing visceral fat to
accumulate in the body. Because skeletal muscle is an insulin-
response target tissue, sarcopenia patients develop progressive
metabolic syndrome.
Adipose tissue secretes proinflammatory cytokines such as
tumor necrosis factor α and interleukin-6, thereby regulating
carbohydrate and fat metabolism. These cytokines are also
associated with protein degradation; thus, sarcopenia can be
accelerated in individuals with long-standing obesity. Therefore,
especially in the elderly population, obesity and sarcopenia
should also be considered as sarcopenic obesity (42).
Our study has several strengths over previous studies. First,
our data were collected from a health checkup cohort. Most
health checkup centers routinely obtain patients’ anthropometric
measurements, including weight, height, and skeletal muscle
mass. Not only obesity but also sarcopenia and sarcopenic
obesity can be diagnosed through this routine measurement.
However, most physicians focus on obesity. Based on our
study, this routine measurement may be a useful tool for
predicting gastric carcinogenesis. Second, our study analyzed
risk factors for gastric carcinogenesis, including gastric cancer
and precancerous conditions. Gastric cancer is one of the
heterogeneous cancers that involves a multistep process from
precancerous conditions to cancer. Therefore, the result of our
study indicates the importance of controlling the risk factors of
gastric carcinogenesis.
Our study also had several limitations. First, because our
data were obtained from an asymptomatic and healthy checkup
cohort, only a few patients diagnosed with gastric cancer who
underwent screening endoscopy were enrolled in this study.
Therefore, a large-scale study is warranted to confirm our
results. Second, patient information, such as medical history,
alcohol consumption, smoking, and diet, was collected using a
questionnaire. However, the questionnaire did not include the
exact amount of alcohol consumption, frequency of smoking,
and amount and concentration of food components consumed.
Third, although current definitions, such as those of the
European Working Group on Sarcopenia in Older People,
the European Society for Clinical Nutrition and Metabolism
Special Interest Groups, and the International Working Group
on Sarcopenia, define sarcopenia as muscle mass and function
(8, 43–45), our study adopted onlymusclemass. This was because
our checkup center did not have a device to measure muscle
function. Most checkup centers’ routine programs only include
muscle mass. Therefore, the result of our study may be sufficient
to predict gastric carcinogenesis in healthy subjects. Fourth,
precancerous conditions, including AG and IM, were diagnosed
only based on gross endoscopic findings rather than on
biopsy. However, the diagnosis of precancerous conditions was
considered reliable as the endoscopists had sufficient experience
(at least 3 years) in diagnosing these types of conditions.
In conclusion, sarcopenia and sarcopenic obesitymay be novel
risk factors for gastric carcinogenesis. Hence, controlling SMI
and BMI as estimators of sarcopenia and sarcopenic obesity
may be important for preventing gastric cancer. Our study only
identified the association between sarcopenia and sarcopenic
obesity and gastric carcinogenesis to prove our hypothesis.
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Therefore, further research should be performed to clarify the
precise mechanism of this association.
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